PHAXIAM Therapeutics (PHXM) Competitors

$3.10 0.00 (0.00%)

As of 05/4/2026

PHXM vs. SNSE, RNTX, ZYBT, ATHE, and HOWL

Should you be buying PHAXIAM Therapeutics stock or one of its competitors? The main competitors of PHAXIAM Therapeutics include Sensei Biotherapeutics (SNSE), Rein Therapeutics (RNTX), Zhengye Biotechnology (ZYBT), Alterity Therapeutics (ATHE), and Werewolf Therapeutics (HOWL). These companies are all part of the "pharmaceutical products" industry.

How does PHAXIAM Therapeutics compare to Sensei Biotherapeutics?

PHAXIAM Therapeutics (NASDAQ:PHXM) and Sensei Biotherapeutics (NASDAQ:SNSE) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, media sentiment, risk and dividends.

: 0.4% of PHAXIAM Therapeutics shares are owned by institutional investors. Comparatively, 10.5% of Sensei Biotherapeutics shares are owned by institutional investors. 1.9% of PHAXIAM Therapeutics shares are owned by company insiders. Comparatively, 23.2% of Sensei Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
: PHAXIAM Therapeutics has a beta of 2.35, indicating that its stock price is 135% more volatile than the S&P 500. Comparatively, Sensei Biotherapeutics has a beta of -0.18, indicating that its stock price is 118% less volatile than the S&P 500.
: Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
PHAXIAM Therapeutics N/A N/A -$240K N/A N/A
Sensei Biotherapeutics N/A N/A -$21.08M -$16.67 N/A
: Sensei Biotherapeutics has a consensus target price of $40.00, indicating a potential upside of 54.68%. Given Sensei Biotherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Sensei Biotherapeutics is more favorable than PHAXIAM Therapeutics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PHAXIAM Therapeutics
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Sensei Biotherapeutics
1 Sell rating(s)

2 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
: PHAXIAM Therapeutics' return on equity of 0.00% beat Sensei Biotherapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
PHAXIAM Therapeutics N/A N/A N/A
Sensei Biotherapeutics N/A -83.59% -69.97%
: In the previous week, Sensei Biotherapeutics had 2 more articles in the media than PHAXIAM Therapeutics. MarketBeat recorded 2 mentions for Sensei Biotherapeutics and 0 mentions for PHAXIAM Therapeutics. Sensei Biotherapeutics' average media sentiment score of 0.55 beat PHAXIAM Therapeutics' score of 0.00 indicating that Sensei Biotherapeutics is being referred to more favorably in the news media.
Company Overall Sentiment
PHAXIAM Therapeutics Neutral
Sensei Biotherapeutics Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PHAXIAM Therapeutics	N/A	N/A	-$240K	N/A	N/A
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$16.67	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PHAXIAM Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Sensei Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Net Margins	Return on Equity	Return on Assets
PHAXIAM Therapeutics	N/A	N/A	N/A
Sensei Biotherapeutics	N/A	-83.59%	-69.97%

Company	Overall Sentiment
PHAXIAM Therapeutics	Neutral
Sensei Biotherapeutics	Positive

Summary

Sensei Biotherapeutics beats PHAXIAM Therapeutics on 7 of the 11 factors compared between the two stocks.

How does PHAXIAM Therapeutics compare to Rein Therapeutics?

PHAXIAM Therapeutics (NASDAQ:PHXM) and Rein Therapeutics (NASDAQ:RNTX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, media sentiment, risk and dividends.

: 0.4% of PHAXIAM Therapeutics shares are owned by institutional investors. Comparatively, 90.9% of Rein Therapeutics shares are owned by institutional investors. 1.9% of PHAXIAM Therapeutics shares are owned by company insiders. Comparatively, 5.1% of Rein Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
: PHAXIAM Therapeutics has a beta of 2.35, indicating that its stock price is 135% more volatile than the S&P 500. Comparatively, Rein Therapeutics has a beta of 1.42, indicating that its stock price is 42% more volatile than the S&P 500.
: Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
PHAXIAM Therapeutics N/A N/A -$240K N/A N/A
Rein Therapeutics N/A N/A -$49.87M -$1.96 N/A
: Rein Therapeutics has a consensus target price of $8.00, indicating a potential upside of 684.31%. Given Rein Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Rein Therapeutics is more favorable than PHAXIAM Therapeutics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PHAXIAM Therapeutics
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Rein Therapeutics
1 Sell rating(s)

1 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
: PHAXIAM Therapeutics' return on equity of 0.00% beat Rein Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
PHAXIAM Therapeutics N/A N/A N/A
Rein Therapeutics N/A -510.35% -56.38%
: In the previous week, Rein Therapeutics had 2 more articles in the media than PHAXIAM Therapeutics. MarketBeat recorded 2 mentions for Rein Therapeutics and 0 mentions for PHAXIAM Therapeutics. PHAXIAM Therapeutics' average media sentiment score of 0.00 equaled Rein Therapeutics'average media sentiment score.
Company Overall Sentiment
PHAXIAM Therapeutics Neutral
Rein Therapeutics Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PHAXIAM Therapeutics	N/A	N/A	-$240K	N/A	N/A
Rein Therapeutics	N/A	N/A	-$49.87M	-$1.96	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PHAXIAM Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Rein Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Net Margins	Return on Equity	Return on Assets
PHAXIAM Therapeutics	N/A	N/A	N/A
Rein Therapeutics	N/A	-510.35%	-56.38%

Company	Overall Sentiment
PHAXIAM Therapeutics	Neutral
Rein Therapeutics	Neutral

Summary

Rein Therapeutics beats PHAXIAM Therapeutics on 6 of the 10 factors compared between the two stocks.

How does PHAXIAM Therapeutics compare to Zhengye Biotechnology?

PHAXIAM Therapeutics (NASDAQ:PHXM) and Zhengye Biotechnology (NASDAQ:ZYBT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, media sentiment, valuation and risk.

: PHAXIAM Therapeutics has a beta of 2.35, suggesting that its share price is 135% more volatile than the S&P 500. Comparatively, Zhengye Biotechnology has a beta of -2.47, suggesting that its share price is 347% less volatile than the S&P 500.
: In the previous week, Zhengye Biotechnology's average media sentiment score of 0.69 beat PHAXIAM Therapeutics' score of 0.00 indicating that Zhengye Biotechnology is being referred to more favorably in the news media.
Company Overall Sentiment
PHAXIAM Therapeutics Neutral
Zhengye Biotechnology Positive
: Company Net Margins Return on Equity Return on Assets
PHAXIAM Therapeutics N/A N/A N/A
Zhengye Biotechnology N/A N/A N/A
: 0.4% of PHAXIAM Therapeutics shares are held by institutional investors. 1.9% of PHAXIAM Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
: PHAXIAM Therapeutics has higher earnings, but lower revenue than Zhengye Biotechnology.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
PHAXIAM Therapeutics N/A N/A -$240K N/A N/A
Zhengye Biotechnology $16.64M 2.69 -$9.98M N/A N/A
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PHAXIAM Therapeutics
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Zhengye Biotechnology
1 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00

Company	Overall Sentiment
PHAXIAM Therapeutics	Neutral
Zhengye Biotechnology	Positive

Company	Net Margins	Return on Equity	Return on Assets
PHAXIAM Therapeutics	N/A	N/A	N/A
Zhengye Biotechnology	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PHAXIAM Therapeutics	N/A	N/A	-$240K	N/A	N/A
Zhengye Biotechnology	$16.64M	2.69	-$9.98M	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PHAXIAM Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Zhengye Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

PHAXIAM Therapeutics beats Zhengye Biotechnology on 4 of the 7 factors compared between the two stocks.

How does PHAXIAM Therapeutics compare to Alterity Therapeutics?

PHAXIAM Therapeutics (NASDAQ:PHXM) and Alterity Therapeutics (NASDAQ:ATHE) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, media sentiment, valuation and risk.

: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PHAXIAM Therapeutics
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Alterity Therapeutics
1 Sell rating(s)

1 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
: In the previous week, Alterity Therapeutics had 2 more articles in the media than PHAXIAM Therapeutics. MarketBeat recorded 2 mentions for Alterity Therapeutics and 0 mentions for PHAXIAM Therapeutics. PHAXIAM Therapeutics' average media sentiment score of 0.00 beat Alterity Therapeutics' score of -0.43 indicating that PHAXIAM Therapeutics is being referred to more favorably in the media.
Company Overall Sentiment
PHAXIAM Therapeutics Neutral
Alterity Therapeutics Neutral
: Company Net Margins Return on Equity Return on Assets
PHAXIAM Therapeutics N/A N/A N/A
Alterity Therapeutics N/A N/A N/A
: Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
PHAXIAM Therapeutics N/A N/A -$240K N/A N/A
Alterity Therapeutics N/A N/A -$7.87M N/A N/A
: 0.4% of PHAXIAM Therapeutics shares are held by institutional investors. Comparatively, 2.1% of Alterity Therapeutics shares are held by institutional investors. 1.9% of PHAXIAM Therapeutics shares are held by insiders. Comparatively, 38.8% of Alterity Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
: PHAXIAM Therapeutics has a beta of 2.35, suggesting that its share price is 135% more volatile than the S&P 500. Comparatively, Alterity Therapeutics has a beta of 0.34, suggesting that its share price is 66% less volatile than the S&P 500.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PHAXIAM Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Alterity Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Overall Sentiment
PHAXIAM Therapeutics	Neutral
Alterity Therapeutics	Neutral

Company	Net Margins	Return on Equity	Return on Assets
PHAXIAM Therapeutics	N/A	N/A	N/A
Alterity Therapeutics	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PHAXIAM Therapeutics	N/A	N/A	-$240K	N/A	N/A
Alterity Therapeutics	N/A	N/A	-$7.87M	N/A	N/A

Summary

Alterity Therapeutics beats PHAXIAM Therapeutics on 5 of the 8 factors compared between the two stocks.

How does PHAXIAM Therapeutics compare to Werewolf Therapeutics?

Werewolf Therapeutics (NASDAQ:HOWL) and PHAXIAM Therapeutics (NASDAQ:PHXM) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk, media sentiment and analyst recommendations.

: Werewolf Therapeutics presently has a consensus target price of $3.75, indicating a potential upside of 459.95%. Given Werewolf Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Werewolf Therapeutics is more favorable than PHAXIAM Therapeutics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Werewolf Therapeutics
1 Sell rating(s)
4 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
2.14
PHAXIAM Therapeutics
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: In the previous week, Werewolf Therapeutics had 9 more articles in the media than PHAXIAM Therapeutics. MarketBeat recorded 9 mentions for Werewolf Therapeutics and 0 mentions for PHAXIAM Therapeutics. PHAXIAM Therapeutics' average media sentiment score of 0.00 beat Werewolf Therapeutics' score of -0.71 indicating that PHAXIAM Therapeutics is being referred to more favorably in the news media.
Company Overall Sentiment
Werewolf Therapeutics Negative
PHAXIAM Therapeutics Neutral
: PHAXIAM Therapeutics' return on equity of 0.00% beat Werewolf Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Werewolf Therapeutics N/A -158.82% -69.75%
PHAXIAM Therapeutics N/A N/A N/A
: PHAXIAM Therapeutics has lower revenue, but higher earnings than Werewolf Therapeutics.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Werewolf Therapeutics $1.88M 17.31 -$60.82M -$1.36 N/A
PHAXIAM Therapeutics N/A N/A -$240K N/A N/A
: 64.8% of Werewolf Therapeutics shares are held by institutional investors. Comparatively, 0.4% of PHAXIAM Therapeutics shares are held by institutional investors. 23.6% of Werewolf Therapeutics shares are held by insiders. Comparatively, 1.9% of PHAXIAM Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
: Werewolf Therapeutics has a beta of 0.41, suggesting that its stock price is 59% less volatile than the S&P 500. Comparatively, PHAXIAM Therapeutics has a beta of 2.35, suggesting that its stock price is 135% more volatile than the S&P 500.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Werewolf Therapeutics	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
PHAXIAM Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Overall Sentiment
Werewolf Therapeutics	Negative
PHAXIAM Therapeutics	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Werewolf Therapeutics	N/A	-158.82%	-69.75%
PHAXIAM Therapeutics	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Werewolf Therapeutics	$1.88M	17.31	-$60.82M	-$1.36	N/A
PHAXIAM Therapeutics	N/A	N/A	-$240K	N/A	N/A

Summary

Werewolf Therapeutics beats PHAXIAM Therapeutics on 7 of the 12 factors compared between the two stocks.

Get PHAXIAM Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PHXM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PHXM vs. The Competition

Export

Metric	PHAXIAM Therapeutics	Biotechnology Industry	Medical Sector	NASDAQ Exchange
Market Cap	$10.58M	$446.06M	$6.25B	$11.87B
Dividend Yield	N/A	3.86%	2.73%	5.21%
P/E Ratio	N/A	4.19	29.04	28.48
Price / Sales	N/A	6,879.71	476.48	60.89
Price / Cash	N/A	13.13	27.62	36.52
Price / Book	0.39	77.74	9.67	6.67
Net Income	-$240K	-$96.07M	$3.55B	$332.64M
7 Day Performance	N/A	0.71%	1.70%	2.01%
1 Month Performance	N/A	3.87%	5.62%	9.19%
1 Year Performance	N/A	48.54%	34.42%	39.59%

PHAXIAM Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PHXM PHAXIAM Therapeutics	N/A	$3.10 flat	N/A	N/A	$10.58M	N/A	N/A	49
SNSE Sensei Biotherapeutics	1.7582 of 5 stars	$29.11 -7.7%	$40.00 +37.4%	N/A	$42.30M	N/A	N/A	40	News Coverage Positive News High Trading Volume
RNTX Rein Therapeutics	2.2911 of 5 stars	$1.45 -2.7%	$8.00 +451.7%	N/A	$41.78M	N/A	N/A	9	Gap Up
ZYBT Zhengye Biotechnology	0.7171 of 5 stars	$0.92 +4.7%	N/A	N/A	$41.76M	$25.53M	N/A	278	Positive News Earnings Report
ATHE Alterity Therapeutics	0.9237 of 5 stars	$4.58 -0.9%	N/A	N/A	$40.97M	N/A	N/A	10

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PHXM) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PHAXIAM Therapeutics (PHXM) Competitors

PHXM vs. SNSE, RNTX, ZYBT, ATHE, and HOWL

How does PHAXIAM Therapeutics compare to Sensei Biotherapeutics?

Summary

How does PHAXIAM Therapeutics compare to Rein Therapeutics?

Summary

How does PHAXIAM Therapeutics compare to Zhengye Biotechnology?

Summary

How does PHAXIAM Therapeutics compare to Alterity Therapeutics?

Summary

How does PHAXIAM Therapeutics compare to Werewolf Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHXM vs. The Competition

PHAXIAM Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PHAXIAM Therapeutics (PHXM) Competitors

PHXM vs. SNSE, RNTX, ZYBT, ATHE, and HOWL

How does PHAXIAM Therapeutics compare to Sensei Biotherapeutics?

Summary

How does PHAXIAM Therapeutics compare to Rein Therapeutics?

Summary

How does PHAXIAM Therapeutics compare to Zhengye Biotechnology?

Summary

How does PHAXIAM Therapeutics compare to Alterity Therapeutics?

Summary

How does PHAXIAM Therapeutics compare to Werewolf Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHXM vs. The Competition

PHAXIAM Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools